bloodstream infection
Conditions
Interventions
intervention group:contezolid tablets
Sponsors
Ethics Committee of Blood Diseases Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Male or female aged >= 18 years; 2. Conform to the diagnostic criteria of febrile neutropenia, clinical diagnosis of blood stream infection (BSI) and etiological diagnosis criteria, and confirm the blood stream infection of gram-positive bacteria, and the infection of other parts with or without it (such as pneumonia or skin and soft tissue infection); 3. Subjects (or their legal representatives/guardians) understand the steps and contents of the study, sign the informed consent form, and are willing to participate in the study.
Exclusion criteria
Exclusion criteria: 1. Those who are allergic tocontezolid tablets or have severe allergic constitution (such as allergic dermatitis and bronchial asthma); 2. Those who cannot be administered orally or are not suitable for administration through nasal feeding/gastrointestinal nutrition tube, or have gastrointestinal diseases that will seriously affect the absorption of oral drugs; 3. Expected survival time3 times, or alanine aminotransferase [ALT] or aspartate aminotransferase [AST] >= 5 times the upper limit of normal value [ULN]; 5. CrCl = 500 msec); 7. In the first month before enrollment, he has received the intervention clinical research of other drugs or medical devices; 8. The investigator believes that it is not suitable to participate in this clinical study or have influence on the endpoint evaluation due to various reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| efficacy; | — |
Secondary
| Measure | Time frame |
|---|---|
| pharmacokinetic characteristics;safety; | — |
Countries
China
Contacts
Public ContactSizhou Feng
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China
Outcome results
None listed